A study of treatment results of the cancer of the eye following different treatment modalities.

Not Applicable

• Conditions: Health Condition 1: C692- Malignant neoplasm of retina

• Registration Number: CTRI/2022/10/046696
• Lead Sponsor: DR RAJENDRA PRASAD CENTRE FOR OPHTHALMIC SCIENCES

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.TUMOR HEIGHT >6MM 2.TUMORS INVOLVING FOVEA 3.ANY MEDIA HAZE PRECLUDING THE VISIBILITY OF TUMOR LIKE VITREOUS HAEMORRHAGE/ VITREOUS SEEDS 4.LARGELY CALCIFIED TUMORS 5.NOT WILLING TO GIVE ONSENT

Exclusion Criteria

1.TUMOR HEIGHT >6MM 2.TUMORS INVOLVING FOVEA 3.ANY MEDIA HAZE PRECLUDING THE VISIBILITY OF TUMOR LIKE VITREOUS HAEMORRHAGE/ VITREOUS SEEDS 4.LARGELY CALCIFIED TUMORS 5.NOT WILLING TO GIVE ONSENT

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate if ICG enhanced TTT achieves greater reduction in Tumor height as compared to TTT alone in thick Retinoblastoma.Timepoint: Outcome will be assessed at baseline, 3weeks, 6weeks, 9weeks,12weeks under EUA OR till tumor height of less than 2mm, whichever is achieved earlier.

Secondary Outcome Measures

Name	Time	Method
To compare the complication rate between 2 groups.Timepoint: Outcome will be assessed at baseline, 3weeks, 6weeks, 9weeks,12weeks under EUA OR till tumor height of less than 2mm, whichever is achieved earlier.